Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG7314 Mechanism of Action Study in Healthy Men
NCT02205073Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of balovaptan in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Roche. Primary endpoints: Replication of AVP-induced inhibition of anterior cingulate cortex (ACC) activity at Day 6, Replication of AVP-induced inhibition of functional connectivity at Day 6 and 1 more. Started Jul 2014; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02205073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205073.